Seres Therapeutics Stock Price, News & Analysis (NASDAQ:MCRB)

$9.66 +0.15 (+1.58 %)
(As of 02/22/2018 04:00 PM ET)
Previous Close$9.66
Today's Range$9.55 - $9.85
52-Week Range$7.90 - $17.42
Volume226,119 shs
Average Volume135,627 shs
Market Capitalization$391.52 million
P/E Ratio-4.56
Dividend YieldN/A
BetaN/A

About Seres Therapeutics (NASDAQ:MCRB)

Seres Therapeutics logoSeres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI; SER-287 and SER-301, to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens.

Receive MCRB News and Ratings via Email

Sign-up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:MCRB
CUSIPN/A
Phone+1-617-9459626

Debt

Debt-to-Equity Ratio0.11%
Current Ratio6.53%
Quick Ratio6.53%

Price-To-Earnings

Trailing P/E Ratio-4.55660377358491
Forward P/E Ratio-4.15
P/E GrowthN/A

Sales & Book Value

Annual Sales$21.77 million
Price / Sales17.98
Cash FlowN/A
Price / CashN/A
Book Value$3.29 per share
Price / Book2.94

Profitability

Trailing EPS($2.12)
Net Income$-91,570,000.00
Net Margins-267.15%
Return on Equity-82.11%
Return on Assets-36.25%

Miscellaneous

Employees127
Outstanding Shares40,530,000

Seres Therapeutics (NASDAQ:MCRB) Frequently Asked Questions

What is Seres Therapeutics' stock symbol?

Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."

How were Seres Therapeutics' earnings last quarter?

Seres Therapeutics Inc (NASDAQ:MCRB) posted its quarterly earnings data on Wednesday, November, 8th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.39) by $0.22. The biotechnology company earned $23 million during the quarter, compared to the consensus estimate of $17.29 million. Seres Therapeutics had a negative net margin of 267.15% and a negative return on equity of 82.11%. Seres Therapeutics's quarterly revenue was up 76.9% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.46) EPS. View Seres Therapeutics' Earnings History.

When will Seres Therapeutics make its next earnings announcement?

Seres Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March, 14th 2018. View Earnings Estimates for Seres Therapeutics.

Where is Seres Therapeutics' stock going? Where will Seres Therapeutics' stock price be in 2018?

9 Wall Street analysts have issued 1 year price objectives for Seres Therapeutics' stock. Their predictions range from $16.00 to $20.00. On average, they expect Seres Therapeutics' share price to reach $18.75 in the next year. View Analyst Ratings for Seres Therapeutics.

What are Wall Street analysts saying about Seres Therapeutics stock?

Here are some recent quotes from research analysts about Seres Therapeutics stock:

  • 1. According to Zacks Investment Research, "Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (1/10/2018)
  • 2. Cowen Inc analysts commented, "Seres reported top-line results from a Phase 1b trial of SER-287 in 58 patients with." (10/2/2017)

Who are some of Seres Therapeutics' key competitors?

Who are Seres Therapeutics' key executives?

Seres Therapeutics' management team includes the folowing people:

  • Roger Pomerantz M.D., Chairman of the Board, President, Chief Executive Officer (Age 60)
  • Eric D. Shaff, Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer (Age 42)
  • John G. Aunins Ph.D., Chief Technology Officer, Executive Vice President - Bioprocess and Manufacturing (Age 56)
  • David N. Cook Ph.D., Chief Scientific Officer, Executive Vice President - Research & Development (Age 59)
  • Thomas J. DesRosier J.D., Chief Legal Officer, Executive Vice President and Secretary (Age 62)
  • Michele Trucksis Ph.D. M.D., Chief Medical Officer and Executive Vice President (Age 64)
  • Noubar B. Afeyan, Lead Independent Director (Age 55)
  • Willard H. Dere M.D., Director (Age 63)
  • Dennis A. Ausiello M.D., Independent Director (Age 71)
  • Gregory Behar, Independent Director (Age 47)

When did Seres Therapeutics IPO?

(MCRB) raised $101 million in an IPO on Friday, June 26th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.

Who owns Seres Therapeutics stock?

Seres Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.58%), ARK Investment Management LLC (4.01%), Renaissance Technologies LLC (2.25%), Artal Group S.A. (0.74%), Millennium Management LLC (0.73%) and Jennison Associates LLC (0.56%). Company insiders that own Seres Therapeutics stock include David N Cook, Eric D Shaff, John G Aunins, Michele Trucksis, Roger Pomerantz and Ventures Fund 2007 L Flagship. View Institutional Ownership Trends for Seres Therapeutics.

Who sold Seres Therapeutics stock? Who is selling Seres Therapeutics stock?

Seres Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A., BlackRock Inc. and Schwab Charles Investment Management Inc.. Company insiders that have sold Seres Therapeutics company stock in the last year include David N Cook and John G Aunins. View Insider Buying and Selling for Seres Therapeutics.

Who bought Seres Therapeutics stock? Who is buying Seres Therapeutics stock?

Seres Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Renaissance Technologies LLC, Jennison Associates LLC, Citadel Advisors LLC, Deutsche Bank AG, Millennium Management LLC, Spark Investment Management LLC and Geode Capital Management LLC. View Insider Buying and Selling for Seres Therapeutics.

How do I buy Seres Therapeutics stock?

Shares of Seres Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Seres Therapeutics' stock price today?

One share of Seres Therapeutics stock can currently be purchased for approximately $9.66.

How big of a company is Seres Therapeutics?

Seres Therapeutics has a market capitalization of $391.52 million and generates $21.77 million in revenue each year. The biotechnology company earns $-91,570,000.00 in net income (profit) each year or ($2.12) on an earnings per share basis. Seres Therapeutics employs 127 workers across the globe.

How can I contact Seres Therapeutics?

Seres Therapeutics' mailing address is 200 Sidney St, CAMBRIDGE, MA 02139-4218, United States. The biotechnology company can be reached via phone at +1-617-9459626.


MarketBeat Community Rating for Seres Therapeutics (MCRB)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  193 (Vote Outperform)
Underperform Votes:  144 (Vote Underperform)
Total Votes:  337
MarketBeat's community ratings are surveys of what our community members think about Seres Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Seres Therapeutics (NASDAQ:MCRB) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $18.75$18.75$18.75$18.25
Price Target Upside: 72.49% upside72.49% upside72.49% upside41.36% upside

Seres Therapeutics (NASDAQ:MCRB) Consensus Price Target History

Price Target History for Seres Therapeutics (NASDAQ:MCRB)

Seres Therapeutics (NASDAQ:MCRB) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/13/2017CIBCInitiated CoverageOutperform -> Outperform$19.00N/AView Rating Details
10/12/2017OppenheimerInitiated CoverageOutperform$19.00N/AView Rating Details
10/12/2017CitigroupInitiated CoverageOutperform -> Positive$19.00N/AView Rating Details
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$20.00N/AView Rating Details
10/2/2017CowenReiterated RatingBuyHighView Rating Details
8/30/2017Cantor FitzgeraldReiterated RatingBuyLowView Rating Details
8/4/2017HC WainwrightReiterated RatingBuy -> Buy$15.00 -> $19.00HighView Rating Details
8/3/2017Canaccord GenuitySet Price TargetBuy$20.00LowView Rating Details
3/20/2017FBR & CoReiterated RatingOutperform$18.00LowView Rating Details
8/11/2016Leerink SwannReiterated RatingBuy$12.00N/AView Rating Details
8/1/2016Bank of AmericaDowngradeBuy -> NeutralN/AView Rating Details
3/3/2016GuggenheimInitiated CoverageBuy$41.00N/AView Rating Details
2/22/2016Goldman Sachs GroupLower Price Target$35.00 -> $34.00N/AView Rating Details
(Data available from 2/22/2016 forward)

Earnings

Seres Therapeutics (NASDAQ:MCRB) Earnings History and Estimates Chart

Earnings by Quarter for Seres Therapeutics (NASDAQ:MCRB)

Seres Therapeutics (NASDAQ MCRB) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/14/2018($0.74)N/AView Earnings Details
11/8/2017Q3 2017($0.39)($0.17)$17.29 million$23.00 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.59)($0.69)$3.00 million$3.00 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.65)($0.63)$3.00 million$3.02 millionViewListenView Earnings Details
3/16/2017Q4 2016($0.70)($0.63)$3.00 million$3.00 millionViewN/AView Earnings Details
11/10/2016Q316($0.55)($0.46)$10.38 million$13.02 millionViewListenView Earnings Details
8/11/2016Q216($0.46)($0.70)$4.20 million$3.00 millionViewListenView Earnings Details
5/16/2016Q116($0.48)($0.50)$1.25 million$2.71 millionViewListenView Earnings Details
2/25/2016Q4 2015($0.40)($0.41)ViewN/AView Earnings Details
11/10/2015Q315($0.32)($0.38)ViewListenView Earnings Details
8/6/2015Q215($0.30)($1.45)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Seres Therapeutics (NASDAQ:MCRB) Earnings Estimates

2018 EPS Consensus Estimate: ($2.65)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.64)($0.64)($0.64)
Q2 20181($0.65)($0.65)($0.65)
Q3 20181($0.67)($0.67)($0.67)
Q4 20181($0.69)($0.69)($0.69)
Q1 20191($0.73)($0.73)($0.73)
Q2 20191($0.24)($0.24)($0.24)
Q3 20191($0.29)($0.29)($0.29)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Seres Therapeutics (NASDAQ:MCRB)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Seres Therapeutics (NASDAQ MCRB) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 41.90%
Institutional Ownership Percentage: 81.78%
Insider Trades by Quarter for Seres Therapeutics (NASDAQ:MCRB)
Insider Trades by Quarter for Seres Therapeutics (NASDAQ:MCRB)

Seres Therapeutics (NASDAQ MCRB) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/26/2018David N CookInsiderSell1,738$11.02$19,152.76141,673View SEC Filing  
12/19/2017John G AuninsInsiderSell1,623$10.14$16,457.2261,060View SEC Filing  
8/29/2016John G AuninsInsiderSell9,390$10.87$102,069.30192,125View SEC Filing  
7/28/2016Michele TrucksisInsiderSell4,156$35.18$146,208.084,156View SEC Filing  
7/27/2016Michele TrucksisInsiderSell38,064$35.14$1,337,568.9638,064View SEC Filing  
7/25/2016John G AuninsInsiderSell9,390$34.18$320,950.20220,155View SEC Filing  
7/6/2016Roger PomerantzCEOSell88,211$29.45$2,597,813.95236,468View SEC Filing  
7/1/2016Roger PomerantzCEOSell56,789$29.81$1,692,880.09240,481View SEC Filing  
6/30/2016Eric D ShaffCFOSell4,533$29.54$133,904.824,533View SEC Filing  
6/28/2016Eric D ShaffCFOSell5,001$28.28$141,428.283,334View SEC Filing  
6/27/2016John G AuninsEVPSell9,390$27.23$255,689.7032,655View SEC Filing  
6/2/2016David N CookEVPSell8,000$31.00$248,000.00136,673View SEC Filing  
6/2/2016Roger PomerantzCEOSell74,049$32.52$2,408,073.48257,741View SEC Filing  
6/1/2016David N CookEVPSell16,000$29.43$470,880.00144,673View SEC Filing  
6/1/2016Roger PomerantzCEOSell70,951$30.51$2,164,715.01254,643View SEC Filing  
5/25/2016Ventures Fund 2007 L FlagshipMajor ShareholderSell1,000,000$27.60$27,600,000.00View SEC Filing  
5/24/2016Roger PomerantzCEOSell9,801$30.00$294,030.00193,493View SEC Filing  
5/6/2016Roger PomerantzCEOSell8,507$24.31$206,805.1731,234View SEC Filing  
5/5/2016Roger PomerantzCEOSell59,325$26.13$1,550,162.2551,325View SEC Filing  
5/3/2016Roger PomerantzCEOSell67,367$28.70$1,933,432.9066,414View SEC Filing  
4/25/2016John G AuninsEVPSell18,640$31.94$595,361.6056,060View SEC Filing  
4/7/2016David N CookEVPSell8,000$31.00$248,000.00160,673View SEC Filing  
4/7/2016Roger PomerantzCEOSell9,212$30.00$276,360.0024,439View SEC Filing  
4/4/2016David N CookEVPSell61,000$26.16$1,595,760.00183,023View SEC Filing  
4/4/2016Eric D ShaffCFOSell6,568$28.85$189,486.806,568View SEC Filing  
4/4/2016Roger PomerantzCEOSell135,788$27.20$3,693,433.60113,690View SEC Filing  
3/31/2016Eric D ShaffCFOSell7,663$26.30$201,536.907,663View SEC Filing  
3/28/2016Eric D ShaffCFOSell5,473$24.07$131,735.115,473View SEC Filing  
3/28/2016John G AuninsEVPSell9,390$23.89$224,327.1074,700View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Seres Therapeutics (NASDAQ MCRB) News Headlines

Source:
DateHeadline
Seres Therapeutics Inc (MCRB) Expected to Post Quarterly Sales of $3.00 MillionSeres Therapeutics Inc (MCRB) Expected to Post Quarterly Sales of $3.00 Million
www.americanbankingnews.com - February 20 at 12:32 PM
Seres Therapeutics Inc (MCRB) Expected to Post Earnings of -$0.73 Per ShareSeres Therapeutics Inc (MCRB) Expected to Post Earnings of -$0.73 Per Share
www.americanbankingnews.com - February 18 at 5:08 AM
Seres Therapeutics Inc (MCRB) Given Average Rating of "Buy" by AnalystsSeres Therapeutics Inc (MCRB) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - February 9 at 1:48 AM
Financial Analysis: Seres Therapeutics (MCRB) versus Its RivalsFinancial Analysis: Seres Therapeutics (MCRB) versus Its Rivals
www.americanbankingnews.com - February 5 at 9:48 AM
Zacks: Analysts Anticipate Seres Therapeutics Inc (MCRB) Will Post Quarterly Sales of $3.00 MillionZacks: Analysts Anticipate Seres Therapeutics Inc (MCRB) Will Post Quarterly Sales of $3.00 Million
www.americanbankingnews.com - February 3 at 6:56 AM
Seres Therapeutics Announces Appointment of Eric D. Shaff to Additional Role of Chief Operating OfficerSeres Therapeutics Announces Appointment of Eric D. Shaff to Additional Role of Chief Operating Officer
finance.yahoo.com - January 31 at 9:03 AM
David N. Cook Sells 1,738 Shares of Seres Therapeutics Inc (MCRB) StockDavid N. Cook Sells 1,738 Shares of Seres Therapeutics Inc (MCRB) Stock
www.americanbankingnews.com - January 30 at 9:18 PM
Seres Therapeutics (MCRB) and Its Competitors Head-To-Head SurveySeres Therapeutics (MCRB) and Its Competitors Head-To-Head Survey
www.americanbankingnews.com - January 18 at 3:28 PM
Seres Therapeutics Inc (MCRB) Expected to Announce Quarterly Sales of $3.00 MillionSeres Therapeutics Inc (MCRB) Expected to Announce Quarterly Sales of $3.00 Million
www.americanbankingnews.com - January 17 at 2:50 PM
Critical Contrast: Verastem (VSTM) vs. Seres Therapeutics (MCRB)Critical Contrast: Verastem (VSTM) vs. Seres Therapeutics (MCRB)
www.americanbankingnews.com - January 15 at 1:16 PM
Seres Therapeutics Inc (MCRB) Given Average Rating of "Buy" by BrokeragesSeres Therapeutics Inc (MCRB) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - January 15 at 1:38 AM
Comparing Seres Therapeutics (MCRB) & The CompetitionComparing Seres Therapeutics (MCRB) & The Competition
www.americanbankingnews.com - January 14 at 1:42 PM
Financial Comparison: Catabasis Pharmaceuticals (CATB) versus Seres Therapeutics (MCRB)Financial Comparison: Catabasis Pharmaceuticals (CATB) versus Seres Therapeutics (MCRB)
www.americanbankingnews.com - January 8 at 11:06 PM
Seres Therapeutics Inc to Post FY2022 Earnings of ($0.30) Per Share, Oppenheimer Forecasts (MCRB)Seres Therapeutics Inc to Post FY2022 Earnings of ($0.30) Per Share, Oppenheimer Forecasts (MCRB)
www.americanbankingnews.com - January 8 at 8:40 PM
Seres Therapeutics (MCRB) Announces SER-287 Phase 1b Microbiome Analyses that Provide Mechanistic Support for ... - StreetInsider.comSeres Therapeutics (MCRB) Announces SER-287 Phase 1b Microbiome Analyses that Provide Mechanistic Support for ... - StreetInsider.com
www.streetinsider.com - January 5 at 4:50 PM
Seres Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare ConferenceSeres Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 9:45 AM
Seres Therapeutics Reports SER-287 Phase 1b Microbiome Analyses that Provide Mechanistic Support for Clinical Efficacy in Ulcerative ColitisSeres Therapeutics Reports SER-287 Phase 1b Microbiome Analyses that Provide Mechanistic Support for Clinical Efficacy in Ulcerative Colitis
finance.yahoo.com - January 4 at 9:45 AM
$3.00 Million in Sales Expected for Seres Therapeutics Inc (MCRB) This Quarter$3.00 Million in Sales Expected for Seres Therapeutics Inc (MCRB) This Quarter
www.americanbankingnews.com - December 31 at 8:58 AM
ETFs with exposure to Seres Therapeutics, Inc. : December 26, 2017ETFs with exposure to Seres Therapeutics, Inc. : December 26, 2017
finance.yahoo.com - December 28 at 5:51 AM
Seres Therapeutics, Inc. :MCRB-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017Seres Therapeutics, Inc. :MCRB-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
finance.yahoo.com - December 25 at 6:46 PM
Seres Therapeutics Inc (MCRB) Receives Consensus Recommendation of "Buy" from BrokeragesSeres Therapeutics Inc (MCRB) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - December 21 at 2:04 AM
John G. Aunins Sells 1,623 Shares of Seres Therapeutics Inc (MCRB) StockJohn G. Aunins Sells 1,623 Shares of Seres Therapeutics Inc (MCRB) Stock
www.americanbankingnews.com - December 20 at 6:28 PM
Seres Therapeutics, Inc. is trading above its 50 day moving average : MCRB-US : December 20, 2017Seres Therapeutics, Inc. is trading above its 50 day moving average : MCRB-US : December 20, 2017
finance.yahoo.com - December 20 at 9:52 AM
 Brokerages Expect Seres Therapeutics Inc (MCRB) Will Post Quarterly Sales of $3.00 Million Brokerages Expect Seres Therapeutics Inc (MCRB) Will Post Quarterly Sales of $3.00 Million
www.americanbankingnews.com - December 14 at 3:22 PM
Seres Therapeutics (MCRB) Raised to "Buy" at Zacks Investment ResearchSeres Therapeutics (MCRB) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - December 10 at 8:07 PM
Seres Therapeutics (MCRB) Announces FDA Orphan Drug Designation for SER-287 in Treatment of Pediatric UCSeres Therapeutics (MCRB) Announces FDA Orphan Drug Designation for SER-287 in Treatment of Pediatric UC
www.streetinsider.com - December 4 at 5:03 PM
Seres Therapeutics Announces FDA Orphan Drug Designation for SER-287 in Treatment of Pediatric Ulcerative Colitis - Business Wire (press release)Seres Therapeutics Announces FDA Orphan Drug Designation for SER-287 in Treatment of Pediatric Ulcerative Colitis - Business Wire (press release)
www.businesswire.com - December 4 at 9:49 AM
Seres shares drop 7% after news of FDA orphan drug designation for ulcerative colitis therapySeres shares drop 7% after news of FDA orphan drug designation for ulcerative colitis therapy
finance.yahoo.com - December 4 at 9:49 AM
Seres Therapeutics Announces FDA Orphan Drug Designation for SER-287 in Treatment of Pediatric Ulcerative ColitisSeres Therapeutics Announces FDA Orphan Drug Designation for SER-287 in Treatment of Pediatric Ulcerative Colitis
finance.yahoo.com - December 4 at 9:49 AM
$3.00 Million in Sales Expected for Seres Therapeutics, Inc. (MCRB) This Quarter$3.00 Million in Sales Expected for Seres Therapeutics, Inc. (MCRB) This Quarter
www.americanbankingnews.com - November 26 at 10:28 AM
Seres Therapeutics, Inc. (MCRB) Receives Average Rating of "Buy" from BrokeragesSeres Therapeutics, Inc. (MCRB) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - November 26 at 1:38 AM
Seres Therapeutics, Inc. (MCRB) Upgraded to Hold at Zacks Investment ResearchSeres Therapeutics, Inc. (MCRB) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - November 25 at 10:52 PM
 Analysts Expect Seres Therapeutics, Inc. (MCRB) to Announce -$0.76 EPS Analysts Expect Seres Therapeutics, Inc. (MCRB) to Announce -$0.76 EPS
www.americanbankingnews.com - November 24 at 9:34 AM
Seres Therapeutics, MD Anderson Cancer Center, and the Parker Institute for Cancer Immunotherapy Announce a Collaboration to Support the Investigation of Microbiome ...Seres Therapeutics, MD Anderson Cancer Center, and the Parker Institute for Cancer Immunotherapy Announce a Collaboration to Support the Investigation of Microbiome ...
www.businesswire.com - November 15 at 6:14 AM
Seres Therapeutics, MD Anderson Cancer Center, and the Parker Institute for Cancer Immunotherapy Announce a Collaboration to Support the Investigation of Microbiome Therapeutics for Immuno-OncologySeres Therapeutics, MD Anderson Cancer Center, and the Parker Institute for Cancer Immunotherapy Announce a Collaboration to Support the Investigation of Microbiome Therapeutics for Immuno-Oncology
finance.yahoo.com - November 15 at 6:14 AM
Seres teams up with MD Anderson to explore guts role in drug responseSeres teams up with MD Anderson to explore gut's role in drug response
finance.yahoo.com - November 15 at 6:14 AM
FY2017 Earnings Estimate for Seres Therapeutics, Inc. (MCRB) Issued By Oppenheimer HoldingsFY2017 Earnings Estimate for Seres Therapeutics, Inc. (MCRB) Issued By Oppenheimer Holdings
www.americanbankingnews.com - November 13 at 2:58 AM
FY2017 EPS Estimates for Seres Therapeutics, Inc. Lifted by Analyst (MCRB)FY2017 EPS Estimates for Seres Therapeutics, Inc. Lifted by Analyst (MCRB)
www.americanbankingnews.com - November 13 at 2:58 AM
Leerink Swann Weighs in on Seres Therapeutics, Inc.s FY2017 Earnings (MCRB)Leerink Swann Weighs in on Seres Therapeutics, Inc.'s FY2017 Earnings (MCRB)
www.americanbankingnews.com - November 13 at 2:58 AM
Edited Transcript of MCRB earnings conference call or presentation 8-Nov-17 1:00pm GMTEdited Transcript of MCRB earnings conference call or presentation 8-Nov-17 1:00pm GMT
finance.yahoo.com - November 8 at 10:22 PM
Seres Therapeutics Awarded Grant from CARB-X to Support Development of Microbiome Therapeutic Candidate - Business Wire (press release)Seres Therapeutics Awarded Grant from CARB-X to Support Development of Microbiome Therapeutic Candidate - Business Wire (press release)
www.businesswire.com - November 8 at 5:21 PM
Seres Therapeutics (MCRB) CEO Roger Pomerantz on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaSeres Therapeutics' (MCRB) CEO Roger Pomerantz on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 8 at 5:21 PM
Seres Therapeutics Awarded Grant from CARB-X to Support Development of Microbiome Therapeutic CandidateSeres Therapeutics Awarded Grant from CARB-X to Support Development of Microbiome Therapeutic Candidate
finance.yahoo.com - November 8 at 5:21 PM
Seres Therapeutics Reports Third Quarter 2017 Financial Results and Provides Update on Operational ProgressSeres Therapeutics Reports Third Quarter 2017 Financial Results and Provides Update on Operational Progress
finance.yahoo.com - November 8 at 5:21 PM
Seres Therapeutics reports 3Q lossSeres Therapeutics reports 3Q loss
finance.yahoo.com - November 8 at 5:21 PM
Seres Therapeutics to Participate in Three Upcoming November ConferencesSeres Therapeutics to Participate in Three Upcoming November Conferences
finance.yahoo.com - November 8 at 5:21 PM
Seres Therapeutics, Inc. (MCRB) Issues Quarterly  Earnings ResultsSeres Therapeutics, Inc. (MCRB) Issues Quarterly Earnings Results
www.americanbankingnews.com - November 8 at 2:39 PM
$18.01 Million in Sales Expected for Seres Therapeutics, Inc. (MCRB) This Quarter$18.01 Million in Sales Expected for Seres Therapeutics, Inc. (MCRB) This Quarter
www.americanbankingnews.com - November 7 at 4:16 AM
Zacks: Analysts Anticipate Seres Therapeutics, Inc. (MCRB) to Post -$0.40 EPSZacks: Analysts Anticipate Seres Therapeutics, Inc. (MCRB) to Post -$0.40 EPS
www.americanbankingnews.com - November 5 at 9:36 AM
Seres Therapeutics to Host Third Quarter 2017 Financial Results and Operational Progress Conference Call and Webcast on November 8, 2017Seres Therapeutics to Host Third Quarter 2017 Financial Results and Operational Progress Conference Call and Webcast on November 8, 2017
finance.yahoo.com - November 3 at 4:49 PM

SEC Filings

Seres Therapeutics (NASDAQ:MCRB) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Seres Therapeutics (NASDAQ:MCRB) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Seres Therapeutics (NASDAQ MCRB) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.